| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Orchestra BioMed Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.61 |
| 52 Week High | US$11.69 |
| 52 Week Low | US$4.22 |
| Beta | 0.43 |
| 11 Month Change | -9.37% |
| 3 Month Change | -29.79% |
| 1 Year Change | -9.37% |
| 33 Year Change | -42.73% |
| 5 Year Change | n/a |
| Change since IPO | -50.79% |
Recent News & Updates
Shareholder Returns
| OBIO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -16.3% | -1.4% | -4.4% |
| 1Y | -9.4% | 14.0% | 19.1% |
Return vs Industry: OBIO underperformed the US Medical Equipment industry which returned 14% over the past year.
Return vs Market: OBIO underperformed the US Market which returned 19.1% over the past year.
Price Volatility
| OBIO volatility | |
|---|---|
| OBIO Average Weekly Movement | 13.2% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OBIO's share price has been volatile over the past 3 months.
Volatility Over Time: OBIO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 56 | David Hochman | orchestrabiomed.com |
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices.
Orchestra BioMed Holdings, Inc. Fundamentals Summary
| OBIO fundamental statistics | |
|---|---|
| Market cap | US$212.20m |
| Earnings (TTM) | -US$55.58m |
| Revenue (TTM) | US$2.08m |
102.1x
P/S Ratio-3.8x
P/E RatioIs OBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBIO income statement (TTM) | |
|---|---|
| Revenue | US$2.08m |
| Cost of Revenue | US$166.00k |
| Gross Profit | US$1.91m |
| Other Expenses | US$57.49m |
| Earnings | -US$55.58m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.47 |
| Gross Margin | 92.02% |
| Net Profit Margin | -2,673.26% |
| Debt/Equity Ratio | 0% |
How did OBIO perform over the long term?
See historical performance and comparison